

# Karl Swedberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5438586/karl-swedberg-publications-by-year.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244  
papers

36,249  
citations

74  
h-index

189  
g-index

273  
ext. papers

43,145  
ext. citations

10.6  
avg, IF

6.71  
L-index

#	Paper	IF	Citations
244	Person-Centred Care, Theory, Operationalisation and Effects. <i>Intelligent Systems Reference Library</i> , <b>2022</b> , 23-33	0.8	
243	Effects of a Person-Centered eHealth Intervention for Patients on Sick Leave Due to Common Mental Disorders (PROMISE Study): Open Randomized Controlled Trial.. <i>JMIR Mental Health</i> , <b>2022</b> , 9, e30966	6	0
242	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	6
241	Growth differentiation factor 15 predicts poor prognosis in patients with heart failure and reduced ejection fraction and anemia: results from RED-HF. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 111, 440	6.1	2
240	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008052	7.6	4
239	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a PARADIGM-HF analysis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1346-1356	12.3	2
238	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1961-1973	15.1	7
237	Heart failure subtypes: Pathophysiology and definitions. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 175, 108815	7.4	0
236	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1308-1320	6.1	1
235	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008075	7.6	2
234	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1518-1524	12.3	7
233	Testing cost containment of future healthcare with maintained or improved quality-The COSTCARES project. <i>Health Science Reports</i> , <b>2021</b> , 4, e309	2.2	1
232	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1334-1349	6.1	1
231	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1234-1248	6.1	3
230	Effects of person-centred care via telephone on self-efficacy in patients with chronic obstructive pulmonary disease: Subgroup analysis of a randomized controlled trial. <i>Nursing Open</i> , <b>2021</b> , 8, 927-935	2.1	3
229	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e019238	6	3
228	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , <b>2021</b> , 237, 45-53	4.9	2

227	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
226	Effects of Person-Centered Care Using a Digital Platform and Structured Telephone Support for People With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Randomized Controlled Trial.. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e26794	7.6	0
225	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006541	7.6	31
224	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 432-441	16.2	22
223	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2123-2133	12.3	22
222	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , <b>2020</b> , 141, 352-361	16.7	145
221	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 528-538	12.3	16
220	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 844-855	7.9	18
219	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM-HF. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3355	3.7	3
218	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2370-2379	12.3	9
217	Person-centred care by a combined digital platform and structured telephone support for people with chronic obstructive pulmonary disease and/or chronic heart failure: study protocol for the PROTECT randomised controlled trial. <i>BMJ Open</i> , <b>2020</b> , 10, e036356	3	7
216	Person-centred eHealth intervention for patients on sick leave due to common mental disorders: study protocol of a randomised controlled trial and process evaluation (PROMISE). <i>BMJ Open</i> , <b>2020</b> , 10, e037515	3	1
215	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , <b>2019</b> , 140, 1369-1379	16.7	28
214	Outcomes and Effect of Treatment According to Etiology in HF <sub>r</sub> EF: An Analysis of PARADIGM-HF. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 457-465	7.9	54
213	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 418-427	7.9	10
212	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 665-675	12.3	145
211	Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial. <i>PharmacoEconomics - Open</i> , <b>2019</b> , 3, 495-504	2.1	12
210	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 336-346	7.9	42

209	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 337-341	12.3	69
208	The Evolution of $\beta$ -Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 672-682	15.1	16
207	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 601-612	15.1	40
206	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 974-984	12.3	30
205	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 1199-1207	3.7	7
204	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 345-351	12.3	28
203	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e006539	7.6	36
202	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 806-814	6.1	5
201	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 29-40	15.1	86
200	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 577-587	12.3	22
199	The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 40-49	12.3	31
198	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 498-505	16.2	57
197	Renal Effects and Associated Outcomes During Angiotensin-Nepriylsin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 489-498	7.9	138
196	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor in Patients With Heart Failure). <i>Circulation</i> , <b>2018</b> , 138, 1077-1087	7.6	34
195	Hyporesponsiveness to Darbeoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbeoetin Alfa in Heart Failure): Clinical and Prognostic Associations. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004431	7.6	7
194	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 760-768	12.3	44
193	The year in cardiology 2017: heart failure. <i>European Heart Journal</i> , <b>2018</b> , 39, 832-839	9.5	4
192	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 564-569	7.9	18

191	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 268-277	12.3	25
190	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 373-381	12.3	24
189	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 295-303	12.3	41
188	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 255-260	3	4
187	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1315-1322	12.3	62
186	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 514-522	12.3	20
185	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 504-510	12.3	37
184	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Nepriylsin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1027-1034	16.2	20
183	Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic ChagasS cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 1069-1071	3.7	12
182	Effects of a person-centred telephone-support in patients with chronic obstructive pulmonary disease and/or chronic heart failure - A randomized controlled trial. <i>PLoS ONE</i> , <b>2018</b> , 13, e0203031	3.7	32
181	Comments on meta-analysis of ivabradine as adjuvant treatment for chronic heart failure by Mizzaci et al. <i>International Journal of Cardiology</i> , <b>2017</b> , 239, 2	3.2	
180	Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 449-456	12.3	10
179	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 317-326	7.9	57
178	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 399-407	7.9	22
177	Achieving a Maximally Tolerated $\beta$ Blocker Dose in Heart Failure Patients: Is There Room For Improvement?. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2542-2550	15.1	23
176	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1230-1241	12.3	24
175	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2606-2618	15.1	47
174	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , <b>2017</b> , 38, 1132-1143	9.5	109

173	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 718-727	12.3	15
172	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1186-1197	12.3	55
171	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. <i>American Heart Journal</i> , <b>2017</b> , 188, 35-41	4.9	24
170	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 333-340	18.1	164
169	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , <b>2017</b> , 31, 545-549	3.9	35
168	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	37
167	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , <b>2017</b> , 38, 742-750	9.5	25
166	Effects of person-centred care after an event of acute coronary syndrome: Two-year follow-up of a randomised controlled trial. <i>International Journal of Cardiology</i> , <b>2017</b> , 249, 42-47	3.2	29
165	Health-Related Quality of Life Outcomes in PARADIGM-HF. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	91
164	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	34
163	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2490-2500	15.1	65
162	Declining Risk of Sudden Death in Heart Failure. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 41-51	59.2	232
161	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. <i>Cardiology</i> , <b>2017</b> , 136, 138-144	1.6	12
160	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 79-85	16.2	84
159	Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 129-137	12.3	68
158	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 241-249	12.3	15
157	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With	16.7	28
156	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	53

155	Effectiveness of person-centred care after acute coronary syndrome in relation to educational level: Subgroup analysis of a two-armed randomised controlled trial. <i>International Journal of Cardiology</i> , <b>2016</b> , 221, 957-62	3.2	30
154	Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 241-248	15.1	81
153	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1771-8	3	23
152	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	35
151	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1175-81	12.3	11
150	Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	201
149	Optimizing the Management of Heart Failure With Preserved Ejection Fraction in the Elderly by Targeting Comorbidities (OPTIMIZE-HFPEF). <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 539-44	3.3	19
148	Health-care improvements in a financially constrained environment. <i>Lancet, The</i> , <b>2016</b> , 387, 646-647	40	13
147	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 611-616	3	11
146	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002744	7.6	100
145	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 152-158	7.9	73
144	Person-centred care for patients with chronic heart failure - a cost-utility analysis. <i>European Journal of Cardiovascular Nursing</i> , <b>2016</b> , 15, 276-84	3.3	49
143	An eHealth Diary and Symptom-Tracking Tool Combined With Person-Centered Care for Improving Self-Efficacy After a Diagnosis of Acute Coronary Syndrome: A Substudy of a Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , <b>2016</b> , 18, e40	7.6	39
142	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 672-83	12.3	15
141	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	17
140	Challenges to Data Monitoring Committees When Regulatory Authorities Intervene. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1580-4	59.2	14
139	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). <i>Circulation</i> , <b>2016</b> , 133, 2254-62	16.7	96
138	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1182-9	12.3	30

137	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1282-92	3.8	9
136	Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. <i>American Journal of Medicine</i> , <b>2015</b> , 128, 1102-1108.e6	2.4	19
135	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , <b>2015</b> , 36, 2310-7	9.5	20
134	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 518-26	12.3	43
133	Person-centred care after acute coronary syndrome, from hospital to primary care - A randomised controlled trial. <i>International Journal of Cardiology</i> , <b>2015</b> , 187, 693-9	3.2	84
132	Effect of ivabradine on early readmissions after hospitalization for worsening heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 268-9	7.9	3
131	Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 2059-2071	15.1	87
130	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. <i>European Heart Journal</i> , <b>2015</b> , 36, 2576-84	9.5	129
129	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1890-7	3	48
128	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , <b>2015</b> , 131, 43-53	16.7	58
127	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , <b>2015</b> , 36, 669-75	9.5	47
126	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1201-7	12.3	23
125	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1294-301	12.3	51
124	Commentary: Swedish initiative on person centred care. <i>BMJ, The</i> , <b>2015</b> , 350, h160	5.9	55
123	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1022-31	12.3	40
122	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , <b>2015</b> , 36, 1106-14	9.5	37
121	Effect of Combining Ivabradine and $\beta$ Blockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , <b>2015</b> , 131, 218-24	1.6	21
120	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , <b>2015</b> , 36, 1990-7	9.5	245



119	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 790-6 <sup>3</sup>		28
118	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , <b>2015</b> , 131, 54-61	16.7	43 <sup>0</sup>
117	Top ten risk factors for morbidity and mortality in patients with chronic systolic heart failure and elevated heart rate: The SHIFT Risk Model. <i>International Journal of Cardiology</i> , <b>2015</b> , 184, 163-169	3.2	34
116	Heart failure therapies in 2014: Mixed results for heart failure therapies. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 73-5	14.8	3
115	Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 497-503	3	37
114	Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 817-25	12.3	119
113	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 401-8	7.6	27
112	Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 993-1004	59.2	33 <sup>01</sup>
111	The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. <i>European Heart Journal</i> , <b>2014</b> , 35, 2001-9	9.5	199
110	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 590-5	7.6	97
109	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 810-6	12.3	51
108	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 76-85	12.3	56
107	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 426-34	12.3	31
106	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 33-40	12.3	141
105	Disease-specific health status as a predictor of mortality. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 923	12.3	
104	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 895-902	7.6	25
103	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1062-73	12.3	264
102	Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1585-93	15.1	168

101	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1977-1985	15.1	90
100	Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 79-84	12.3	21
99	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1296-303	12.3	51
98	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 885-91	12.3	40
97	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , <b>2013</b> , 167, 1677-87	3.2	82
96	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. <i>Clinical Research in Cardiology</i> , <b>2013</b> , 102, 11-22	6.1	157
95	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 488-96	7.9	49
94	Efficacy of person-centred care as an intervention in controlled trials - a systematic review. <i>Journal of Clinical Nursing</i> , <b>2013</b> , 22, 456-65	3.2	166
93	Treatment of anemia with darbepoetin alfa in systolic heart failure. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1210-9	59.2	331
92	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , <b>2013</b> , 34, 2263-70	9.5	72
91	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , <b>2013</b> , 34, 1404-13	9.5	595
90	Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 711-8	7.6	26
89	Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care. <i>European Journal of Cardiovascular Nursing</i> , <b>2013</b> , 12, 521-8	3.3	63
88	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2823-9	9.5	61
87	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 334-41	12.3	20
86	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1044-52	12.3	19
85	The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 515-23	3.3	51
84	Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1598-603	15.1	189

83	Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1785-95	15.1	119
82	Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart Failure treatment with the I(f) inhibitor ivabradine Trial) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1938-45	15.1	183
81	Effects of person-centred care in patients with chronic heart failure: the PCC-HF study. <i>European Heart Journal</i> , <b>2012</b> , 33, 1112-9	9.5	210
80	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , <b>2012</b> , 33, 2782-95	9.5	121
79	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , <b>2012</b> , 33, 2813-20	9.5	97
78	The beat goes on: on the importance of heart rate in chronic heart failure. <i>European Heart Journal</i> , <b>2012</b> , 33, 1044-5	9.5	6
77	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 11-21	59.2	1890
76	Optimal Pharmacological Therapy in Chronic Heart Failure 2011 - How to Achieve the Standard. <i>Journal of Cardiac Failure</i> , <b>2011</b> , 17, S123-S124	3.3	
75	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , <b>2011</b> , 100, 11-9	6.1	76
74	n-3 Fatty acids in cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 1159; author reply 1159	59.2	4
73	Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 838-45	12.3	14
72	Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study. <i>European Journal of Heart Failure</i> , <b>2011</b> , 13, 1000-5	12.3	17
71	Person-centered care--ready for prime time. <i>European Journal of Cardiovascular Nursing</i> , <b>2011</b> , 10, 248-51	3.3	841
70	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , <b>2011</b> , 32, 2395-404	9.5	141
69	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , <b>2011</b> , 32, 2507-15	9.5	207
68	Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 1233-8	12.3	98
67	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 75-81	12.3	72
66	Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy. <i>Thrombosis Research</i> , <b>2010</b> , 125, e46-50	8.2	7

65	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , <b>2010</b> , 376, 886-94	40	615
64	Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 617-22	12.3	57
63	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , <b>2010</b> , 376, 875-85	40	1646
62	Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 92-8	12.3	53
61	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 1143-51	12.3	95
60	Fallacies in clinical cardiovascular trials. <i>Heart</i> , <b>2009</b> , 95, 1464-8	5.1	2
59	Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 292-8	12.3	77
58	Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. <i>European Heart Journal</i> , <b>2009</b> , 30, 671-8	9.5	74
57	Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 1640-8	15.1	141
56	Successful treatment of heart failure with devices requires collaboration. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 1229-35	12.3	21
55	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2008</b> , 29, 1377-85	9.5	419
54	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 933-89	12.3	1355
53	Reviewers 2006. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 109-109	12.3	
52	Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 795-801	12.3	60
51	Pure heart rate reduction: further perspectives in heart failure. <i>Country Review Ukraine</i> , <b>2007</b> , 9, F20-F24		7
50	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , <b>2007</b> , 116, 1482-7	16.7	400
49	Diagnostic and therapeutic algorithms in chronic heart failure. <i>Herz</i> , <b>2006</b> , 31, 877-90	2.6	1
48	Treatment of chronic heart failure: a comparison between the major guidelines. <i>European Heart Journal</i> , <b>2006</b> , 27, 1773-7	9.5	40

47	Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1997-2004	15.1	406
46	Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. <i>European Heart Journal</i> , <b>2005</b> , 26, 1303-8	9.5	486
45	Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. <i>European Heart Journal</i> , <b>2005</b> , 26, 2706-13	9.5	143
44	Symptoms in patients with heart failure are prognostic predictors: insights from COMET. <i>Journal of Cardiac Failure</i> , <b>2005</b> , 11, 288-92	3.3	145
43	Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. <i>European Heart Journal</i> , <b>2005</b> , 26, 2259-68	9.5	134
42	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. <i>American Heart Journal</i> , <b>2005</b> , 149, 370-6	4.9	61
41	Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. <i>Circulation</i> , <b>2005</b> , 112, 3738-44	16.7	540
40	1446 Assessing Dyspnoea in Patients with Chronic Heart Failure Does Gender Make a Difference?. <i>European Journal of Cardiovascular Nursing</i> , <b>2005</b> , 4, 65-66	3.3	
39	Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. <i>European Heart Journal</i> , <b>2005</b> , 26, 1115-40	9.5	1642
38	Conclusions on the management of heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , <b>2004</b> , 5 Suppl 1, S34-6	3	
37	Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. <i>European Heart Journal</i> , <b>2004</b> , 25, 300-7	9.5	186
36	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. <i>Circulation</i> , <b>2004</b> , 110, 2618-26	16.7	282
35	Beta-blockers in chronic heart failure. <i>Circulation</i> , <b>2003</b> , 107, 1570-5	16.7	120
34	Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 1893-906	59.2	1892
33	Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. <i>Lancet, The</i> , <b>2003</b> , 362, 7-13	40	1400
32	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , <b>2003</b> , 362, 759-66	40	1506
31	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet, The</i> , <b>2003</b> , 362, 767-71	40	1502
30	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , <b>2003</b> , 362, 772-6	40	1362

29	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , <b>2003</b> , 362, 777-81	40	2087
28	Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. <i>Circulation</i> , <b>2002</b> , 105, 1797-803	16.7	80
27	Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. <i>European Journal of Heart Failure</i> , <b>2002</b> , 4, 321-9	12.3	61
26	Skeletal muscle characteristics, muscle strength and thigh muscle area in patients before and after cardiac transplantation. <i>European Journal of Heart Failure</i> , <b>2001</b> , 3, 59-67	12.3	50
25	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 51, 35-43	3.8	13
24	ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality. <i>Annals of Noninvasive Electrocardiology</i> , <b>2001</b> , 6, 198-202	1.5	10
23	Implantable left ventricular assist systems (LVAS): recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure. <i>European Journal of Heart Failure</i> , <b>2000</b> , 2, 13-8	12.3	5
22	Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. <i>European Journal of Heart Failure</i> , <b>2000</b> , 2, 229-33	12.3	20
21	Exploring New Treatment Strategies in Heart Failure. <i>Blood Pressure</i> , <b>2000</b> , 9, 44-48	1.7	2
20	Effects of the Ikr-blocker almokalant and predictors of conversion of chronic atrial tachyarrhythmias to sinus rhythm. A prospective study. <i>Cardiovascular Drugs and Therapy</i> , <b>1999</b> , 13, 329-38	3.9	6
19	Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. <i>PACE - Pacing and Clinical Electrophysiology</i> , <b>1998</b> , 21, 1044-57	1.6	90
18	Acute myocardial infarction: difference in the treatment between men and women. <i>International Journal for Quality in Health Care</i> , <b>1993</b> , 5, 261-5	1.9	24
17	Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 479-87	3	155
16	The effect of treatment on survival in congestive heart failure. <i>Clinical Cardiology</i> , <b>1992</b> , 15, 323-9	3.3	11
15	Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trial. <i>Drugs</i> , <b>1990</b> , 39 Suppl 4, 49-52; discussion 53-4	12.1	7
14	Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction. <i>Acta Medica Scandinavica</i> , <b>1988</b> , 223, 227-31		11
13	QRS amplitudes, QTc intervals and ECG abnormalities in pheochromocytoma patients before, during and after treatment. <i>Acta Medica Scandinavica</i> , <b>1988</b> , 224, 231-5		21
12	Use of nitrates in acute and chronic congestive heart failure. <i>Drugs</i> , <b>1987</b> , 33 Suppl 4, 147-9	12.1	3

11	Self-assessment of quality of life in severe heart failure. An instrument for clinical use. <i>Scandinavian Journal of Psychology</i> , <b>1987</b> , 28, 220-5	2.2	90
10	Effects of ACE-inhibition on regional circulation in congestive heart failure. <i>Acta Medica Scandinavica</i> , <b>1986</b> , 707, 91-3		1
9	Development of tolerance to nitrate therapy in chronic congestive heart failure. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1986</b> , 59 Suppl 6, 49-51		
8	ADP-induced platelet aggregation and metoprolol treatment of myocardial infarction patients. A controlled study. <i>Acta Medica Scandinavica</i> , <b>1985</b> , 217, 15-20		8
7	Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. <i>American Journal of Cardiology</i> , <b>1984</b> , 54, 783-6	3	157
6	Possible adrenergic effects on heart protein metabolism. <i>Acta Medica Scandinavica</i> , <b>1983</b> , 672, 85-93		2
5	Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. <i>Journal of the American College of Cardiology</i> , <b>1983</b> , 2, 865-71	15.1	97
4	Plasma levels of platelet factor 4 in patients admitted to a coronary care unit. <i>Scandinavian Journal of Haematology</i> , <b>1981</b> , 26, 235-40		8
3	Plasma concentrations of platelet factor 4 in acute myocardial infarction. <i>Scandinavian Journal of Haematology</i> , <b>1981</b> , 26, 359-63		2
2	Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. <i>Lancet, The</i> , <b>1979</b> , 1, 1374-6	40	306
1	Hemodynamic effects of the cardioselective beta-blocking agent metoprolol in acute myocardial infarction. A 24-hour catheterization study. <i>Acta Medica Scandinavica</i> , <b>1978</b> , 204, 195-201		17